233 related articles for article (PubMed ID: 19789308)
1. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.
Evageliou NF; Hogarty MD
Clin Cancer Res; 2009 Oct; 15(19):5956-61. PubMed ID: 19789308
[TBL] [Abstract][Full Text] [Related]
2. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
3. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
4. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD
Transl Pediatr; 2015 Jul; 4(3):226-38. PubMed ID: 26835380
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.
Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Di Giacomo S; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M
Sci Transl Med; 2019 Jan; 11(477):. PubMed ID: 30700572
[TBL] [Abstract][Full Text] [Related]
6. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
7. Polyamine synthesis as a target of
Bachmann AS; Geerts D
J Biol Chem; 2018 Nov; 293(48):18757-18769. PubMed ID: 30404920
[TBL] [Abstract][Full Text] [Related]
8. Polyamine metabolism is sensitive to glycolysis inhibition in human neuroblastoma cells.
Ruiz-Pérez MV; Medina MÁ; Urdiales JL; Keinänen TA; Sánchez-Jiménez F
J Biol Chem; 2015 Mar; 290(10):6106-19. PubMed ID: 25593318
[TBL] [Abstract][Full Text] [Related]
9. The c-myc gene regulates the polyamine pathway in DMSO-induced apoptosis.
Trubiani O; Pieri C; Rapino M; Di Primio R
Cell Prolif; 1999; 32(2-3):119-29. PubMed ID: 10535358
[TBL] [Abstract][Full Text] [Related]
10. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.
Gamble LD; Hogarty MD; Liu X; Ziegler DS; Marshall G; Norris MD; Haber M
Front Oncol; 2012; 2():162. PubMed ID: 23181218
[TBL] [Abstract][Full Text] [Related]
11. Myc, Oncogenic Protein Translation, and the Role of Polyamines.
Flynn AT; Hogarty MD
Med Sci (Basel); 2018 May; 6(2):. PubMed ID: 29799508
[TBL] [Abstract][Full Text] [Related]
12. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
14. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
15. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
16. Polyamines modulate transcription but not posttranscription of c-myc and c-jun in IEC-6 cells.
Patel AR; Wang JY
Am J Physiol; 1997 Sep; 273(3 Pt 1):C1020-9. PubMed ID: 9316423
[TBL] [Abstract][Full Text] [Related]
17. The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme.
Urban-Wójciuk Z; Graham A; Barker K; Kwok C; Sbirkov Y; Howell L; Campbell J; Woster PM; Poon E; Petrie K; Chesler L
Cancer Gene Ther; 2022 Jul; 29(7):940-950. PubMed ID: 34522028
[TBL] [Abstract][Full Text] [Related]
18. Significance of targeting polyamine metabolism as an antineoplastic strategy: unique targets for polyamine analogues.
Casero RA; Frydman B; Stewart TM; Woster PM
Proc West Pharmacol Soc; 2005; 48():24-30. PubMed ID: 16416654
[TBL] [Abstract][Full Text] [Related]
19. Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway.
Yang J
Br J Cancer; 2024 Mar; 130(4):513-516. PubMed ID: 38316994
[TBL] [Abstract][Full Text] [Related]
20. Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies.
Murray-Stewart T; Dunworth M; Lui Y; Giardiello FM; Woster PM; Casero RA
PLoS One; 2018; 13(8):e0202677. PubMed ID: 30138353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
